$6.00 BUY rating set by MLV Capital for Galena Biopharma (GA

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks
$6.00 BUY rating set by MLV Capital for Galena Biopharma (GA

An SI Board Since October 2012

Posts	SubjectMarks	Bans	Symbol
0	0	0	GALE

Emcee: Geney	Type: Moderated

Introduction Market Data Compact

I received news PR this morning about Galena Biopharma and wanted to share...

$6.00 BUY rating set by MLV Capital for Galena Biopharma (GALE)

Key Points

• Validated Target NeuVax targets the same antigen as Herceptin®
(trastuzumab), Genentech's (a wholly owned subsidiary of Roche OCT:RHHBY)
$5.6 billion blockbuster monoclonal antibody. However, NeuVax has the
potential to reach more patients, as it is being developed for patients with low
to intermediate HER2/neu oncogene over-expression (classified as HER2/neu
negative) with early stage breast cancer.

• Strong Phase II Data Support Ongoing Registrational Phase III Phase II data
has shown that the Phase III target population of node-positive, HER2/neu
negative patients have increased disease free survival rates at both 24 and 36
month timepoints. 100% of NeuVax treated patients in this population were
alive without disease after 36 months, a statistically significant improvement
over 77.8% in control patients (p=0.035). The FDA has accepted disease-free
survival at 36 months as a primary endpoint for this trial according to an SPA.
Full enrollment of 700 patients is expected by mid-2013.

• Unmet Clinical Need Despite effective initial surgery, chemotherapy and
radiation, patients with no evidence of disease still face the possibility of
disease recurrence. Nearly 25% of breast cancer patients with node-positive
disease will have recurrent breast cancer. NeuVax is given intradermally and
elicits an active immune response that can be visually monitored by clinicians
by virtue of patients displaying a delayed-type hypersensitivity response (DTH)
at the injection site. The ease of administration, we believe, will assist in
adoption of the drug, when and if the vaccine is approved and marketed.

• Potential Partnerships We believe that Galena will be able to maximize value
for investors by forming a partnership agreement after having top-line Phase
III data. If these data are similar to the Phase II data then NeuVax will present
a new therapeutic option for treating breast cancer, and the only one for
patients with early-stage HER2/neu negative disease. We think this makes
NeuVax a potential game changer in the field, and a potentially valuable asset,
and we would be accumulating at current levels of Galena's stock.

Go to reply# or date (mm/dd/yy):